CTS-1027

CTS-1027 is a potent small molecule inhibitor of MMPs, with IC50s of 0.3 nM, 0.5 nM for MMP2, MMP13, respectively, and has > 1,000 fold selectivity over MMP1.

Product Specifications

CAS Number

[193022-04-7]

Product Name Alternative

Ro 1130830; RS 130830

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

MMP

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/CTS-1027.html

Purity

99.24

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(NO)C1(CCOCC1)CS(=O)(C2=CC=C(C=C2)OC3=CC=C(C=C3)Cl)=O

Molecular Formula

C19H20ClNO6S

Molecular Weight

425.88

Precautions

H302, H315, H319, H335

References & Citations

[1]Kahraman A, et al. Matrix metalloproteinase inhibitor, CTS-1027, attenuates liver injury and fibrosis in the bile duct-ligated mouse. Hepatol Res. 2009 Aug;39 (8) :805-813.|[2]Johnson JL, et al. Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability. Cardiovasc Res. 2006 Aug 1;71 (3) :586-595.